Scroll to top

Scroll to top

News Releases

News Releases

Month Year

Month Year

Investor Alerts

Sep 20, 2022

Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects
Sep 1, 2022

Immunic, Inc. to Participate in Investor Conferences in September
Aug 16, 2022

Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium
Aug 4, 2022

Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Aug 2, 2022

Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
Jul 28, 2022

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update
Jul 6, 2022

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén
Jun 28, 2022

Immunic to Participate in Industry and Scientific Conferences in July
Jun 15, 2022

Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology
Jun 8, 2022

Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June
Jun 2, 2022

Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update
May 10, 2022

Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 5, 2022

Immunic Announces Start of Patient Cohorts in Its Phase 1 Clinical Trial of IMU-856 in Celiac Disease
May 3, 2022

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2022 and Provide Corporate Update
Apr 25, 2022

Immunic, Inc. to Participate in Upcoming Investor and Industry Conferences
Mar 16, 2022

Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer
Mar 8, 2022

Immunic, Inc. to Participate in Investor and Scientific Conferences in March
Feb 24, 2022

Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity

- Initiated Enrollment in Phase 3 ENSURE Program of Vidofludimus Calcium for the Treatment of Relapsing Multiple Sclerosis; Final Cohort 2 Data from the Phase 2 EMPhASIS Trial Confirms Phase 3 Dose Selection -
Feb 18, 2022

Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn's and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis

Top-Line Data of the CALDOSE-1 Trial Expected to be Available in June of 2022
Feb 17, 2022

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update

- Webcast to be Held at 8:00 am ET on February 24, 2022 -
Feb 8, 2022

Immunic, Inc. to Participate in Investor and Scientific Conferences in February
Feb 2, 2022

Immunic Receives Notice of Allowance for Composition-of-Matter Patents in the United States and in Europe for IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor
Dec 14, 2021

Immunic, Inc. Publishes Positive Results from the Single and Multiple Ascending Dose Parts of its Phase 1 Clinical Trial of IMU-935, a Potentially Best-in-Class Oral IL-17 Inhibitor

- Unblinded Data Established a Favorable Safety and Tolerability Profile for IMU-935 in Single Dose and 14-Day Multiple Dose Assessments in Healthy Human Subjects -
Dec 9, 2021

Immunic, Inc. Announces Enrollment of the First Patient in its Phase 1 Trial of IMU-935 in Metastatic Castration-Resistant Prostate Cancer
Nov 23, 2021

Immunic, Inc. to Participate in the Piper Sandler & Co. 33rd Annual Virtual Healthcare Conference

Show per page